Exelixis, Inc. (EXEL)
58.56
+1.66
(+2.93%)
USD |
NASDAQ |
Sep 02, 16:00
58.56
0.00 (0.00%)
After-Hours: 18:50
Exelixis Research and Development Expense (TTM) : 824.32M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 824.32M |
| March 31, 2026 | 812.68M |
| December 31, 2025 | 825.00M |
| September 30, 2025 | 860.76M |
| June 30, 2025 | 884.16M |
| March 31, 2025 | 894.95M |
| December 31, 2024 | 910.41M |
| September 30, 2024 | 906.08M |
| June 30, 2024 | 1.016B |
| March 31, 2024 | 1.038B |
| December 31, 2023 | 1.044B |
| September 30, 2023 | 1.136B |
| June 30, 2023 | 1.002B |
| March 31, 2023 | 969.39M |
| December 31, 2022 | 891.81M |
| September 30, 2022 | 777.26M |
| June 30, 2022 | 741.79M |
| March 31, 2022 | 691.10M |
| December 31, 2021 | 693.72M |
| September 30, 2021 | 625.73M |
| June 30, 2021 | 639.12M |
| March 31, 2021 | 605.26M |
| December 31, 2020 | 547.85M |
| September 30, 2020 | 488.02M |
| June 30, 2020 | 408.55M |
| Date | Value |
|---|---|
| March 31, 2020 | 375.55M |
| December 31, 2019 | 336.96M |
| September 30, 2019 | 299.79M |
| June 30, 2019 | 247.23M |
| March 31, 2019 | 207.79M |
| December 31, 2018 | 182.26M |
| September 30, 2018 | 157.19M |
| June 30, 2018 | 140.99M |
| March 31, 2018 | 126.72M |
| December 31, 2017 | 112.17M |
| September 30, 2017 | 103.77M |
| June 30, 2017 | 95.48M |
| March 31, 2017 | 90.25M |
| December 31, 2016 | 95.97M |
| September 30, 2016 | 95.64M |
| June 30, 2016 | 101.47M |
| March 31, 2016 | 103.00M |
| December 31, 2015 | 96.35M |
| September 30, 2015 | 112.53M |
| June 30, 2015 | 130.07M |
| March 31, 2015 | 156.54M |
| December 31, 2014 | 189.10M |
| September 30, 2014 | 199.05M |
| June 30, 2014 | 202.02M |
| March 31, 2014 | 200.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| BioMarin Pharmaceutical, Inc. | 766.68M |
| Cytokinetics, Inc. | 384.41M |
| Emergent BioSolutions, Inc. | 45.30M |
| Gilead Sciences, Inc. | 5.943B |